Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study

Abstract We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued t...

Full description

Saved in:

Bibliographic Details
Published in:	Open forum infectious diseases Vol. 11; no. 8; p. ofae436
Main Authors:	Teresita de Jesús, Cabrera-López, Edgar, Pérez-Barragán, Carlos Ruben, Nava-Campos, Marla, Toiber-Rodríguez, Juan Carlos, Rodríguez-Aldama, Raúl Adrián, Cruz-Flores, Andrea, González-Rodríguez
Format:	Journal Article
Language:	English
Published:	US Oxford University Press 01-08-2024
Subjects:	Infection Prevention and Control INSTI bictegravir/emtricitabine/tenofovir alafenamide HIV sexual assault post-exposure prophylaxis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Drs. Cabrera López and Pérez Barragán contributed equally to this article. Potential conflicts of interest. All authors: No reported conflicts.
ISSN:	2328-8957 2328-8957
DOI:	10.1093/ofid/ofae436